29,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Die zerebrale Amyloidangiopathie (CAA) ist eine Erkrankung, bei der sich beta-Amyloid in den Gefäßwänden des Gehirns ablagert. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
All articles of this category (opens in new window) Die zerebrale Amyloidangiopathie (CAA) ist eine Erkrankung, bei der sich beta-Amyloid in den Gefäßwänden des Gehirns ablagert. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Wissenschaftler*innen der Washington Universität in St. Louis untersuchten in dieser aktuellen Studie Machbarkeit und Sicherheit der Therapie mit dem monoklonalen Antikörper Lecanemab bei Patientinnen und Patienten mit früher symptomatischer Alzheimer-Krankheit. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Eine Möglichkeit zur Behandlung von beginnenden Alzheimer-Erkrankungen stellten Anti-Amyloid-Antikörper (AK) dar, die die Amyloidablagerungen im Gehirn reduzieren sollen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mit der Zulassung von Lecanemab in Europa ist die Antikörpertherapie bei Alzheimer Krankheit (AD) hierzulande angekommen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease is one of the causes of dementia that could make the patient lose their memories until they unable to do normal activities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Progressive neurodegenerative disorder i.e. Alzheimer’s disease (AD) is characterized by cognitive decline, oxidative stress, and cholinergic dysfunction, β-amyloid aggregation, tau hyperphosphorylation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On June 7, 2021, the FDA granted accelerated approval to aducanumab (Aduhelm), the first new Alzheimer's drug approved since 2003 and the first ever approved for a mechanism thought to modify disease course. 3 key findings →
Design: regulatory decision Evidence: preliminary
Full summary, score breakdown and related studies → Original source
Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. 3 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ImportanceThe ASPREE randomized trial found no overall benefit of low-dose aspirin for disability-free survival among older adults. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
BackgroundAnti-amyloid-{beta} (A{beta}) monoclonal antibodies are disease-modifying treatments for early Alzheimers disease but are associated with amyloid-related imaging abnormalities (ARIA) and intracranial hemorrhage (ICH). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundNon-pharmacological interventions may enhance motor-cognitive integration in prodromal Alzheimers disease (pAD). 5 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
IntroductionRemote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. 3 key findings →
Design: longitudinal study Participants: 209 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Aggregation of the microtubule-stabilizing protein Tau into insoluble deposits is characteristic for several neurodegenerative diseases, including Alzheimer's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's Disease (AD), the most common neurodegenerative disease in the world, is caused by a variety of factors that lead to neuronal injury and an alteration in neurotransmitter production and release. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In this cohort, APOE ε4 carrier status was related to disease severity at baseline rather than to the rate of cognitive decline over 80 weeks. 3 key findings →
Design: clinical trial Participants: 370 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Structural studies of amyloid fibrils extracted from brain tissue have identified disease-specific fibril polymorphs. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid-β (Aβ) immunotherapy improves cognitive outcomes in Alzheimer’s disease (AD) but is associated with amyloid-related imaging abnormalities (ARIA), through poorly understood mechanisms. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
CSF Aβ42 rose from 526.0 to 1053.0 pg/mL (+ 100.2%), total tau (t-tau) fell from 578.2 to 278.0 pg/mL(-51.9%), and phosphorylated tau181 (p-tau181) fell from 90.8 to 23.1 pg/mL(-74.6%). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease disrupts large-scale brain networks before cognitive symptoms emerge, yet the mechanisms underlying this progression remain unclear. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From 464 identified records, 30 peer-reviewed primary studies met all eligibility criteria following the exclusion of low-quality sources and unindexed preprints. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Amyloid plaques, one of the defining features of Alzheimer’s disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Artificial intelligence (AI) is now a credible translational research platform across the Alzheimer’s disease (AD) pathway, but its clinical value is often difficult to judge from performance metrics alone. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 29,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 29,380 records, built mostly from automated pulls of Europe PMC (63.3% of the library) and OpenAlex (17.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.5% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →